Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 1/20 | 0.74 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.59 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.59 |
| ▸ | HTR1D | P28221 | 2/20 | 0.58 |
| ▸ | HTR6 | P50406 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | HPGD | P15428 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | HTR1E | P28566 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | HTR5A | P47898 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8978303 | 0.90 | AKR1C2 (0.67) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL8681515 | 0.89 | AKR1C2 (0.78) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL6825151 | 0.89 | AKR1C2 (0.78) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL30604527 | 0.89 | AKR1C2 (0.78) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL7952956 | 0.87 | HTR6 (0.57) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL14451078 | 0.87 | AKR1C2 (0.66) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL8293076 | 0.86 | MTNR1A (0.62) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 | |
| SCHEMBL3958468 | 0.86 | ALDH1A1 (0.71) | AKR1C2MTNR1AMTNR1BALDH1A1KDM4E | |
| SCHEMBL29628777 | 0.86 | ALDH1A1 (0.71) | AKR1C2MTNR1AMTNR1BALDH1A1KDM4E | |
| SCHEMBL14610676 | 0.86 | AKR1C2 (0.65) | AKR1C2MTNR1AMTNR1BHTR1DHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418902-A4 | NOVEL METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF DYSMENORRHOEA AND MENSTRUAL SIDE EFFECTS: THE USE OF PHOSPHOLIPASE INHIBITORS | UNIV QUEENSLAND (AU) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006099416-A1 | 2-METHYL INDOLE CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| EP-1581491-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040247639-A1 | Novel methods and compositions for the treatment or prevention of dysmenorrhoea and menstrual side effects: the use of phospholipase inhibitors | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-12-09 | — | — | US | disclosed |
| WO-2004092131-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-1418902-A1 | NOVEL METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF DYSMENORRHOEA AND MENSTRUAL SIDE EFFECTS: THE USE OF PHOSPHOLIPASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2004-05-19 | — | — | EP | disclosed |
| WO-2002005808-A1 | NOVEL METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF DYSMENORRHOEA AND MENSTRUAL SIDE EFFECTS: THE USE OF PHOSPHOLIPASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-01-24 | — | — | WO | disclosed |
| US-6252084-B1 | THERAPY FOR SEPSIS SHOCK | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0620215-B1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | LILLY CO ELI (US) | 1999-08-18 | — | — | EP | disclosed |
| EP-0620214-B1 | 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors | LILLY CO ELI (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5684034-A | INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE | ELI LILLY AND COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| US-5578634-A | SEPTIC SHOCK TREATMENT | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| EP-0620214-A1 | 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| US-4160862-A | ANTIINFLAMMATORY | STERLING DRUG INC. (US) | 1979-07-10 | — | — | US | disclosed |
| US-4021431-A | ANTIINFLAMMATORY AGENTS | STERLING DRUG INC. (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040247639-A1 | Novel methods and compositions for the treatment or prevention of dysmenorrhoea and menstrual side effects: the use of phospholipase inhibitors | PLA2G12A, PLA2G1B, PLA2G2E | AKR1C2 3434/4885MTNR1A 279/4885MTNR1B 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.